OncoMatch/Clinical Trials/NCT05266846
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
Is NCT05266846 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pembrolizumab for alk gene mutation.
Treatment: Pembrolizumab — This is an open-label, multiple centers, two-arms phase II study to evaluate the safety and efficacy Pembrolizumab,Bevacizumab in combination with Chemotherapy could improve PFS in Alectinib Failed ALK-rearranged Advanced Lung Adenocarcinoma with Persistent 5'ALK. The eligible patients should have Stage IV Adenocarcinoma ALK-rearranged tested by NGS Perisitent with 5'ALK Failed from first line Alectinib. The patients should meet the physical requirements to receive Pembrolizumab, Bevacizumab with Chemotherapy. All the patients who meet these requirements will be enrolled in this study. The eligible patients will be treated with Pembrolizumab 200 mg intravenously (IV) plus Bevacizumab 15mg/kg+ Pemetrexed 500mg/m2+Carboplatin AUC=4 for up to 4 cycles followed by Pembrolizumab 200mg Q3W+ Bevacizumab 15mg/kg+Pemetrexed 500mg/m2 for up to 31cycles or until disease progression, intolerable toxicity, or physician or participant decision.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK rearrangement
ALK-rearranged Lung Adenocarcinoma
Required: ALK persistent 5'ALK
Persistent with 5'ALK
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: ALK inhibitor (alectinib) — first line
Failed from first line Alectinib
Cannot have received: anti-PD-1 therapy
Prior treatment with anti-programmed death-1
Cannot have received: anti-PD-L1 therapy
Prior treatment with anti-PD-L1 therapeutic antibodies
Cannot have received: anti-VEGF therapy
Prior treatment with anti-VEGF agents
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Adequate end organ function
Liver function
Adequate end organ function
Adequate hematologic and end organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify